CMRX News: Earnings, Analyst Moves, and More





Chimerix, Inc. (CMRX) News

Chimerix, Inc. (CMRX): $3.44

0.02 (-0.58%)

POWR Rating

Component Grades

Momentum

F

Stability

D

Sentiment

Quality

C

Add CMRX to Watchlist
Sign Up

Industry: Biotech

Industry

F

Ranked

#99 of 337

in industry

Filter CMRX News Items

CMRX News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

CMRX News Highlights

  • For CMRX, its 30 day story count is now at 2.
  • Over the past 10 days, the trend for CMRX's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
  • The most mentioned tickers in articles about CMRX are DEC.

Latest CMRX News From Around the Web

Below are the latest news stories about CHIMERIX INC that investors may wish to consider to help them evaluate CMRX as an investment opportunity.

Positive Signs As Multiple Insiders Buy Chimerix Stock

Usually, when one insider buys stock, it might not be a monumental event. But when multiple insiders are buying like...

Yahoo | December 14, 2023

Chimerix Promotes Michelle LaSpaluto to Chief Financial Officer

Proven Leader Brings More Than 25 Years of Financial ExperienceDURHAM, N.C., Dec. 04, 2023 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission is to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases, today announced the promotion of Michelle LaSpaluto, Vice President of Corporate Financial Planning and Investor Relations, to Chief Financial Officer effective December 1, 2023. “We are excited to announce this well

Yahoo | December 4, 2023

Chimerix Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

DURHAM, N.C., Nov. 24, 2023 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), today announced that on November 20, 2023, the Compensation Committee of Chimerix’s Board of Directors granted an inducement award to a new employee of non-qualified stock options to purchase 150,000 shares of Chimerix’s common stock. The Compensation Committee of Chimerix’s Board of Directors approved the award as an inducement material to the new employee’s employment agreement in accordance with Nasdaq Listing rule 5635(c

Yahoo | November 24, 2023

Chimerix Strengthens Executive Leadership Team with Appointment of Thomas Riga as Chief Operating and Commercial Officer

Seasoned Executive Brings More Than 25 Years of Industry Leadership Experience in Oncology Commercialization and Corporate Business DevelopmentDURHAM, N.C., Nov. 16, 2023 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission is to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases, today announced the appointment of Thomas Riga as Chief Operating and Commercial Officer. “We are excited to welcome Tom to the Chimerix

Yahoo | November 16, 2023

Chimerix, Inc. (NASDAQ:CMRX) Q3 2023 Earnings Call Transcript

Chimerix, Inc. (NASDAQ:CMRX) Q3 2023 Earnings Call Transcript November 2, 2023 Chimerix, Inc. misses on earnings expectations. Reported EPS is $-0.27 EPS, expectations were $-0.22. Operator: Good morning, ladies and gentlemen, and welcome to the Chimerix Third Quarter 2023 Earnings Conference Call. I would now like to introduce you to your host for today’s call, […]

Yahoo | November 3, 2023

Chimerix (NASDAQ:CMRX) shareholders have endured a 70% loss from investing in the stock five years ago

Long term investing works well, but it doesn't always work for each individual stock. It hits us in the gut when we see...

Yahoo | November 3, 2023

Q3 2023 Chimerix Inc Earnings Call

Q3 2023 Chimerix Inc Earnings Call

Yahoo | November 3, 2023

Chimerix Inc (CMRX) Reports Q3 2023 Financial Results and Operational Updates

Net Loss of $24.0 Million and Increased R&D Expenses

Yahoo | November 2, 2023

Chimerix Reports Third Quarter 2023 Financial Results and Provides Operational Update

– Phase 3 ACTION Study Ongoing with 113 Sites Activated Across 12 Countries; Interim Survival and PFS Data on Track to Report in 2025 – – Actively Recruiting ONC206 Dose Escalation Studies; Enrollment on Track to Complete First Half 2024 – – Conference Call at 8:30 a.m. ET Today – DURHAM, N.C., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission is to develop medicines that meaningfully improve and extend the lives of patients facing deadly disease

Yahoo | November 2, 2023

Chimerix to Report Third Quarter 2023 Financial Results and Provide an Operational Update on November 2, 2023

DURHAM, N.C., Oct. 26, 2023 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission is to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases, today announced that it will host a live conference call and audio webcast on Thursday, November 2, 2023 at 8:30 a.m. ET to report financial results for the third quarter ended September 30, 2023, and to provide a business overview. To access the live conference call, please dia

Yahoo | October 26, 2023


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!